ATHE - Alterity Therapeutics Ltd. Company Value to Earnings Growth Ratio
The PEG ratio chart demonstrates the commercialization potential of neurotherapy through sales of the ATH434 drug for Alterity Therapeutics (ATHE). The value of 0.00 reflects the baseline level of the metric, while the active pipeline prepares for critical Phase II trial results. The company's strategy relies on capturing unique niches in the treatment of rare brain pathologies and Parkinson's disease.
Alterity Therapeutics (ATHE) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Alterity Therapeutics|ATHE - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio alteritytherapeutics.com|ATHE - Company Total Debt|Debts to Book Value Alterity Therapeutics Ltd|ATHE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Alterity Therapeutics|Intermediate Liquidity Ratio alteritytherapeutics.com
- earnings and multiples data:
ATHE - Net Profit|Expected Net Income Alterity Therapeutics|ATHE - P/E Multiple|Projected Price to Earnings Ratio alteritytherapeutics.com|ATHE - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Alterity Therapeutics Ltd|ATHE - Operating profit EBITDA|Net earnings per share (EPS TTM) Alterity Therapeutics|ATHE - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months alteritytherapeutics.com|ATHE - Earnings growth in current year|Expected net earnings per share growth next year Alterity Therapeutics
Summary company analytics:ATHE - Alterity Therapeutics Ltd.
To objectively evaluate Alterity Therapeutics (ATHE), a manager must compare the asset's market value with its earnings dynamics. The PEG ratio measures the P/E ratio relative to the projected earnings growth rate, where a value below one signals undervaluation. The PEG fundamental indicator on the GURU.Markets platform allows for tracking this balance dynamically. For a biotechnology company utilizing a full-outsourcing development model, this serves as a critical filter for operational risks.
Who Alterity Therapeutics competes with
Price/Earnings to Growth Ratio BIIB (Biogen Inc)|Neurocrine Biosciences Inc - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio RGC (Regencell Corp)|Axsome Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate acadia-pharm.com|Xenon (XENE) - Price/Earnings to Growth Ratio|Viking Therapeutics Inc - Growth-Adjusted Payback Ratio|SUPN (Supernus Pharma) - PEG Multiple|Catalyst Corp (CPRX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|Company Value to Earnings Growth Ratio HRMY|Biohaven - Price/Earnings to Growth Multiple|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL (Anavex Life Sciences) - Price/Earnings to Growth Multiple|CBLL: Company Value to Earnings Growth Ratio|PRTA (Prothena Corporation plc) - PEG Multiple|ALEC: Growth-Adjusted Payback Ratio|PEG Multiple ANNX|OMER - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Neurogene Inc. NGNE|Growth-Adjusted Payback Ratio ACIU|Voyager Therapeutics, Inc. - PEG Multiple|NMRA - PEG Multiple|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio TVGN (Tevogen Bio Inc.)|ACOG (Alpha Cognition Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate cogrx.com CGTX|Price/Earnings to Growth Multiple IKT (Inhibikase Therapeutics, Inc.)|PEG Multiple Cassava Sciences Inc (SAVA)|Assertio - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics Inc. OVID|ABOS: PEG Multiple|Price/Earnings to Growth Multiple CervoMed, Inc.|Price/Earnings to Growth Ratio Clene Inc|PepGen Corp (PEPG) - Growth-Adjusted Market Cap to Net Income|PEG Multiple JUNS|PEG Multiple relmada.com (RLMD)|Annovis Bio - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio GRCE (Grace Therapeutics Inc)|Firefly Neuroscience Inc - PEG Multiple|Growth-Adjusted Payback Ratio KLTO (Klotho Neurosciences Inc)|NRSN: PEG Multiple|Price to Earnings Adjusted for Growth Rate revivapharma.com (RVPH)|Price/Earnings to Growth Ratio MetaVia Inc.|Growth-Adjusted P/E Ratio NRXS (NeurAxis Inc.)|PEG Multiple HSDT|PASG - Price to Earnings Adjusted for Growth Rate|Neuphoria Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple minervaneurosciences.com NERV|ATHA - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ADXN (Addex Therapeutics Ltd.)|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Cyclerion Therapeutics, Inc. (CYCN)|PTIX (Protagenic Therapeutics Inc.) - PEG Multiple|PEG Multiple Pasithea|Price/Earnings to Growth Ratio Cortigent, Inc. (CRGT)|Price/Earnings to Growth Ratio ATXI (Avenue Therapeutics Inc.)|Brainstorm Cell Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio CARA (Cara Therapeutics Inc)|Chromocell Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate Eliem Therapeutics|intracellulartherapies.com (ITCI) - Price/Earnings to Growth Ratio|Longboard Pharmaceuticals Inc - Growth-Adjusted Payback Ratio|MRNS (Marinus) - PEG Multiple|NKGen Biotech Corp (NKGN) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple NRBO (NeuroBo Pharmaceuticals)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix - Price/Earnings to Growth Multiple|Trevena Inc. (TRVN) - Price to Earnings Adjusted for Growth Rate|VIGL: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio WENA (Anew Medical Inc.)|CERE (Cerevel Therapeutics) - Price/Earnings to Growth Multiple
